Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
An aging world population exposed to a sedentary life style is currently plagued by chronic metabolic diseases, such as type-2 diabetes, that are spreading worldwide at an unprecedented rate. One of the most promising pharmacological approaches for the management of type 2 diabetes takes advantage of the peptide hormone glucagon-like peptide-1 (GLP-1) under the form of protease resistant mimetics, and DPP-IV inhibitors. Despite the improved quality of life, long-term treatments with these new classes of drugs are riddled with serious and life-threatening side-effects, with no overall cure of the disease. New evidence is shedding more light over the complex physiology of GLP-1 in health and metabolic diseases. Herein, we discuss the most recent advancements in the biology of gut receptors known to induce the secretion of GLP-1, to bridge the multiple gaps into our understanding of its physiology and pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425 · cited 1×
“Animals’ GI tract is known to host a population of hundreds of different species of bacteria (386), viruses and fungi, estimated to equal in number the cells that constitute the human body (387).”
Backgroundden Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., & Bakker, B. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036012 · Cited by 5,048
Host-gut microbiota metabolic interactions
Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012) · Science · doi:10.1126/science.1223813 · Cited by 4,760 · cited 2×
“The relative abundance of different microbial species is known to depend on the presence of specific nutrients (389); hence, considering that an imbalance in the microbiota correlates with chronic inflammation pathologies of the bowel, or even Type 2 diabetes, it is likely that dietary components indirectly influence…”
BackgroundFunctional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387 · cited 1×
“The relative abundance of different microbial species is known to depend on the presence of specific nutrients (389); hence, considering that an imbalance in the microbiota correlates with chronic inflammation pathologies of the bowel, or even Type 2 diabetes, it is likely that dietary components indirectly influence…”
BackgroundDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Short chain fatty acids in human large intestine, portal, hepatic and venous blood
Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P., & Macfarlane, G. T. (1987) · Gut · doi:10.1136/gut.28.10.1221 · Cited by 3,119
Topping, D. L., & Clifton, P. M. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1031 · Cited by 3,091
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Oh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., & Olefsky, J. M. (2010) · Cell · doi:10.1016/j.cell.2010.07.041 · Cited by 2,428
Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211609200 · Cited by 2,409 · cited 7×
“In pancreatic β-cells, both GPR43 and GPR41 are expressed, and the latter antagonizes GSIS (304).”
BackgroundInfluentialTolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., & Gribble, F. M. (2012) · Diabetes · doi:10.2337/db11-1019 · Cited by 2,404
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Le Poul, E., Loison, C., Struyf, S., Springael, J.-Y., Lannoy, V., Decobecq, M.-E., Brezillon, S., Dupriez, V., Vassart, G., Van Damme, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301403200 · Cited by 1,651
A G Protein-coupled Receptor Responsive to Bile Acids
Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209706200 · Cited by 1,628 · cited 2×
“distributed along the whole gastrointestinal tract of dogs (101, 272, 273).”
BackgroundFree fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538 · cited 1×
“GPR40 is primarily expressed by the pancreatic β-cells, where it plays a pivotal role in FFA-mediated insulin secretion (249) but also in α-cells (78, 250), CCK (80), GIP (251), and GLP-1 (79) producing cells in the gut and in hypothalamic neurons (248, 252, 253).”
BackgroundReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Martin, C. R., Osadchiy, V., Kalani, A., & Mayer, E. A. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.04.003 · Cited by 1,284
Identification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
Vitamin D Receptor As an Intestinal Bile Acid Sensor
Makishima, M., Lu, T. T., Xie, W., Whitfield, G. K., Domoto, H., Evans, R. M., Haussler, M. R., & Mangelsdorf, D. J. (2002) · Science · doi:10.1126/science.1070477 · Cited by 1,176
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 2×
“Some authors postulate the existance of an unknown GLP-1(9-36)NH2 receptor (141, 142), because indeed this cleaved peptide is found in peripheral blood at one order of magnitude higher concentrations than “active” GLP-1 (7-36)NH2 and shows cardioprotection, antioxidant properties (138) and appears capable to also inhi…”
BackgroundGut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995 · cited 2×
“Interestingly, this axis is also activated by the disaccharide sucrose and by the non-metabolizable and therefore anergic sucralose (243).”
BackgroundThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“This signaling has proven to be essential for the Liraglutide mediated weight loss in rats (163).”
BackgroundIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · cited 8×
“Indeed, it has been estimated that just 10-15% of the secreted GLP-1(7-36)NH2 reaches the systemic circulation (117), with some authors reportingmeager peripheral meal-induced changes in both healthy and diabetic people (118).”
BackgroundInfluentialPlasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 8×
“Indeed, it has been estimated that just 10-15% of the secreted GLP-1(7-36)NH2 reaches the systemic circulation (117), with some authors reportingmeager peripheral meal-induced changes in both healthy and diabetic people (118).”
BackgroundResultInfluentialPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803
Katsuma, S., Hirasawa, A., & Tsujimoto, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.139 · Cited by 789 · cited 9×
“Historically described as mere fat-solubilizing agents, these amphipathic compounds were recently recognized as key signaling molecules capable to modulate the host metabolism directly acting as ligands of intestinal GPCRs (101, 338, 339), or after being metabolized by the colonic microbiota into secondary bile acids,…”
BackgroundInfluentialGlucose Sensing in L Cells: A Primary Cell Study
Reimann, F., Habib, A. M., Tolhurst, G., Parker, H. E., Rogers, G. J., & Gribble, F. M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.11.002 · Cited by 733 · cited 14×
“The 1st phase in the pathway of glucose signaling, sees the electrogenic sodium-coupled glucose transporters 1 (SGLT1) mediated uptake of two Na ions for every internalized glucose molecule (53).”
BackgroundResultInfluentialLi, F., Jiang, C., Krausz, K. W., Li, Y., Albert, I., Hao, H., Fabre, K. M., Mitchell, J. B., Patterson, A. D., & Gonzalez, F. J. (2013) · Nature Communications · doi:10.1038/ncomms3384 · Cited by 705 · cited 1×
“Consistently, an indirect inhibition of intestinal FXR through microbiota modulation, or genetic deletion of intestinal FXR, corroborate this phenome displaying protection from highfat diets induced obesity and fatty liver disease (351).”
BackgroundUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 1×
“More recent data suggest how the unimolecular co-activation of GLP-1 and GIP receptors, has powerful anti-diabetic effects superior to either agonism (197).”
BackgroundEnteroendocrine Cells: Chemosensors in the Intestinal Epithelium
Gribble, F. M., & Reimann, F. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105439 · Cited by 683
Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654 · cited 8×
“Multiple cell types found in the enteroendocrine cell system, the pancreatic islets or the brain have been shown to express the GCG product, a 180 aminoacids long peptide known as proglucagon (PG) (106, 107), which gets trimmed tissuedependently into at least 6 different bio-active peptides, namely glicentin, oxyntomo…”
BackgroundInfluentialA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Patti, M., Houten, S. M., Bianco, A. C., Bernier, R., Larsen, P. R., Holst, J. J., Badman, M. K., Maratos‐Flier, E., Mun, E. C., Pihlajamaki, J., et al. (2009) · Obesity · doi:10.1038/oby.2009.102 · Cited by 591 · cited 3×
“GLP-1R expressing hypothalamic neurons have proven dispensable for the beneficial metabolic activity of both BBB permeable Liraglutide and Exending-4 (164).”
BackgroundEdfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587 · cited 4×
“Free fatty acids GLP-1 ↑, GIP ↑ In-vivo mouse (79)”
BackgroundInfluentialNilsson, N. E., Kotarsky, K., Owman, C., & Olde, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00488-1 · Cited by 540
Commensal bacteria make GPCR ligands that mimic human signalling molecules
Cohen, L. J., Esterhazy, D., Kim, S.-H., Lemetre, C., Aguilar, R. R., Gordon, E. A., Pickard, A. J., Cross, J. R., Emiliano, A. B., Han, S. M., et al. (2017) · Nature · doi:10.1038/nature23874 · Cited by 500 · cited 10×
“OEA is a more potent GPR119 agonist than its glycerol ester 2-Oleoyl Glycerol (2-OG) found in olive oil (322).”
BackgroundInfluentialPhysiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498 · cited 2×
“In particular PC1/3 expressing cells, such as intestinal L-cells and pancreatic β-cells, produce GLP-1, GLP-2 oxyntomodulin and glicentin (110, 112), while PC2 action on PG results in the production of glucagon and its active metabolite mini-glucagon (113, 114).”
BackgroundNeuroepithelial circuit formed by innervation of sensory enteroendocrine cells
Bohórquez, D. V., Shahid, R. A., Erdmann, A., Kreger, A. M., Wang, Y., Calakos, N., Wang, F., & Liddle, R. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78361 · Cited by 484 · cited 1×
“Surprisingly, the EECs in the colon have been demonstrated to physically connect through a basal process named Neuropod, with afferent nerve cells residing in the lamina propria, defining a neuroepithelial circuit that expands the physiology of these cells (59).”
BackgroundRichards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472 · cited 1×
“Indeed the GLP-1(7-36) NH2 receptor, a GPCR, is found to be expressed by a wide range of tissues and cells such as: α, β, and δ-cells (169), sinoatrial node myocytes, arterial smooth muscle cells of lungs and kidneys, megakaryocytes, macrophages, monocytes, lymphocytes, gastrointestinal tract mucosa [mainly Brunner’s…”
BackgroundSubcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435 · cited 1×
“Furthermore, oxyntomodulin is a natural dual-agonist of GLP-1 and glucagon receptors and displays anti-diabetic properties in humans (198, 199).”
BackgroundGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347
Parker, H. E., Habib, A. M., Rogers, G. J., Gribble, F. M., & Reimann, F. (2009) · Diabetologia · doi:10.1007/s00125-008-1202-x · Cited by 324 · cited 1×
“GPR40 is primarily expressed by the pancreatic β-cells, where it plays a pivotal role in FFA-mediated insulin secretion (249) but also in α-cells (78, 250), CCK (80), GIP (251), and GLP-1 (79) producing cells in the gut and in hypothalamic neurons (248, 252, 253).”
BackgroundSalehi, M., Prigeon, R. L., & D’Alessio, D. A. (2011) · Diabetes · doi:10.2337/db11-0203 · Cited by 323 · cited 1×
“Curiously, some bariatric RYGB patients experience up to a 10-fold increase in post-meal active GLP-1 plasmatic levels (from fasting 5 pM to post-prandial 30–65 pM) (146), and have a 2- to 3-fold higher glucose-stimulated Insulin secretion (147), which in some diabetic patients results in GLP-1-mediated hyperinsulinem…”
BackgroundGLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288 · cited 1×
“In perspective, GIP and Insulin showmuch broader dynamic ranges, with postmeal levels reaching 300 and 400 pM respectively, from their baselines <20 pM within 30min post glucose ingestion (108, 145).”
BackgroundYusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282
On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane
Moore, B., Edie, E. S., & Abram, J. H. (1906) · Biochemical Journal · doi:10.1042/bj0010028 · Cited by 279 · cited 8×
“Indeed, it has been estimated that just 10-15% of the secreted GLP-1(7-36)NH2 reaches the systemic circulation (117), with some authors reportingmeager peripheral meal-induced changes in both healthy and diabetic people (118).”
BackgroundInfluentialNikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00347.2005 · Cited by 274 · cited 1×
“On the other hand, the most abundant DPP-IV-processed metabolite GLP-1 (9-36)NH2, has also been reported to have biological activities, protecting human aortic endothelial cells and cardiomyocytes in vivo in dogs (137) and ex vivo in mice (138) and rats (139), even in the absence of a GLP-1 Receptor (139, 140).”
BackgroundHost-microbe co-metabolism dictates cancer drug efficacy in C. elegans
Scott, T. A., Quintaneiro, L. M., Norvaisas, P., Lui, P. P., Wilson, M. P., Leung, K.-Y., Herrera-Dominguez, L., Sudiwala, S., Pessia, A., Clayton, P. T., et al. (2017) · Cell · doi:10.1016/j.cell.2017.03.040 · Cited by 254 · cited 1×
“Indeed, the pharmacokinetic and pharmacodynamics of any drug taken by mouth should be appraised considering the role of the microbiota, as the varied efficacy of some chemotherapeutics such as 5-FU has been proven to directly depend on this host-microbiota metabolism (400).”
BackgroundEnteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion
Lebrun, L. J., Lenaerts, K., Kiers, D., Pais de Barros, J.-P., Le Guern, N., Plesnik, J., Thomas, C., Bourgeois, T., Dejong, C. H. C., Kox, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.008 · Cited by 238 · cited 1×
“Furthermore an inflammatory status, as seen in pathologies such as type 2 diabetes, might compromise the gut mucosal permeability, leading to the exposure of intestinal EECs to luminal LPS, and a TLR4-mediated release of GLP-1 (229).”
BackgroundGlucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
Hupe-Sodmann, K., McGregor, G. P., Bridenbaugh, R., Göke, R., Göke, B., Thole, H., Zimmermann, B., & Voigt, K. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00063-h · Cited by 224
The L-cell in nutritional sensing and the regulation of appetite
Spreckley, E. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2015.00023 · Cited by 198 · cited 10×
“Furthermore, concentrations of up to 300mM glucose do not induce GLP-1 secretion from colonic human mucosa because GLP-1 producing L-cells barely express SGLT1 (43, 53, 58, 72).”
BackgroundInfluentialMoriya, R., Shirakura, T., Ito, J., Mashiko, S., & Seo, T. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00412.2009 · Cited by 156 · cited 6×
“Furthermore, concentrations of up to 300mM glucose do not induce GLP-1 secretion from colonic human mucosa because GLP-1 producing L-cells barely express SGLT1 (43, 53, 58, 72).”
BackgroundInfluentialMechanisms controlling glucose-induced GLP-1 secretion in human small intestine
Sun, E. W., de Fontgalland, D., Rabbitt, P., Hollington, P., Sposato, L., Due, S. L., Wattchow, D. A., Rayner, C. K., Deane, A. M., Young, R. L., et al. (2017) · Diabetes · doi:10.2337/db17-0058 · Cited by 152 · cited 7×
“Furthermore, concentrations of up to 300mM glucose do not induce GLP-1 secretion from colonic human mucosa because GLP-1 producing L-cells barely express SGLT1 (43, 53, 58, 72).”
BackgroundInfluentialBile acids and bariatric surgery
Albaugh, V. L., Banan, B., Ajouz, H., Abumrad, N. N., & Flynn, C. R. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.04.001 · Cited by 148 · cited 4×
“In the last three decades a major tenet seeing GLP1 (7-36)NH2, GLP1 (7-37) and the Gastric Insulinotropic Peptide (GIP) as the major contributors of the physiological incretin effect has reached widespread consensus (104).”
BackgroundInfluentialBurmeister, M. A., Ayala, J. E., Smouse, H., Landivar-Rocha, A., Brown, J. D., Drucker, D. J., Stoffers, D. A., Sandoval, D. A., Seeley, R. J., & Ayala, J. E. (2017) · Diabetes · doi:10.2337/db16-1102 · Cited by 136
Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control
Lang Lehrskov, L., Lyngbaek, M. P., Soederlund, L., Legaard, G. E., Ehses, J. A., Heywood, S. E., Wewer Albrechtsen, N. J., Holst, J. J., Karstoft, K., Pedersen, B. K., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.008 · Cited by 135
Is GLP‐1 a hormone: Whether and When?
D'Alessio, D. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12466 · Cited by 130 · cited 1×
“When examining the physiology of glucagon-like peptide-1, it is important to consider that there is an expanding body of evidence that questions its systemic endocrine physiology (203, 204).”
BackgroundJall, S., Sachs, S., Clemmensen, C., Finan, B., Neff, F., DiMarchi, R. D., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.02.002 · Cited by 107 · cited 1×
“The synergistic activation of these three important receptors is capable to revert diet-induced obesity, cognitive impairment and T2D in mice models, warranting future human studies (201, 202).”
BackgroundAyala, J. E., Bracy, D. P., James, F. D., Burmeister, M. A., Wasserman, D. H., & Drucker, D. J. (2010) · Endocrinology · doi:10.1210/en.2010-0289 · Cited by 95
Oxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86 · cited 1×
“In particular PC1/3 expressing cells, such as intestinal L-cells and pancreatic β-cells, produce GLP-1, GLP-2 oxyntomodulin and glicentin (110, 112), while PC2 action on PG results in the production of glucagon and its active metabolite mini-glucagon (113, 114).”
BackgroundCheang, J. Y., & Moyle, P. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201700781 · Cited by 82 · cited 1×
“Nonetheless, the pharmacological activation of the GLP-1R is clinically beneficial (179), offering an improved glycaemic control with lower cardiovascular morbidity and without the risk of hypoglycaemia associated with some current anti diabetic drugs (173).”
BackgroundDiverse signaling systems activated by the sweet taste receptor in human GLP-1-secreting cells
Ohtsu, Y., Nakagawa, Y., Nagasawa, M., Takeda, S., Arakawa, H., & Kojima, I. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.07.004 · Cited by 56 · cited 1×
“Of note also Aspartame, Acesulfame K, Glycyrrhizin and Saccharin bind the sweet receptor heterodimer Tas1R2/3 and they have shown to stimulate GLP-1 secretion in the human duodenal adenocarcinoma-derived HuTu-80 cell line (245, 246).”
BackgroundSundström, L., Myhre, S., Sundqvist, M., Ahnmark, A., McCoull, W., Raubo, P., Groombridge, S. D., Polla, M., Nyström, A.-C., Kristensson, L., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189060 · Cited by 53 · cited 1×
“Expectedly, GPR120 agonism shows powerful anti-diabetic, anorexic, and hepatoprotective properties inmultiple animalmodels (275, 284– 287), at least partially mediated by GLP-1 (288).”
BackgroundChen, T., Tian, P., Huang, Z., Zhao, X., Wang, H., Xia, C., Wang, L., & Wei, H. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9155-6 · Cited by 52 · cited 1×
“This is consistent with the knowledge that GLP1, as well as glucagon, has shown to possess powerful antiinflammatory properties in vivo, an area that hold with vast therapeutical potential (136, 230).”
ResultIntra-islet glucagon-like peptide 1
Fava, G. E., Dong, E. W., & Wu, H. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.016 · Cited by 45 · cited 1×
“Nonetheless, it is also clear that intra-islet GLP1R signaling is essential for GSIS, with more evidence that an intra-islet paracrine GLP-1 signaling is physiologically present (212, 213) and necessary for β-cell health under metabolic (214).”
Background
Cited by
An inter-organ neural circuit for appetite suppression
Zhang, T., Perkins, M. H., Chang, H., Han, W., & de Araujo, I. E. (2022) · Cell · doi:10.1016/j.cell.2022.05.007 · Cited by 192
Kabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating
Brierley, D. I., & de Lartigue, G. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15603 · Cited by 92
Malbert, C.-H., Chauvin, A., Horowitz, M., & Jones, K. L. (2021) · Diabetes · doi:10.2337/db20-0361 · Cited by 18
Chrononutrition: Potential, Challenges, and Application in Managing Obesity
Fuad, S. A., Ginting, R. P., & Lee, M.-W. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115116 · Cited by 16
Metadata
- Authors
- Paternoster, S., & Falasca, M.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2018-10-11
- Volume
- 9
- Pages
- 584-584
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2896479010
- Cited by
- 91
- References
- 75
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.